NCT00606307 2019-12-03Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative DiseasesItalfarmacoPhase 2 Completed29 enrolled 8 charts